Compare · APLS vs KZR
APLS vs KZR
Side-by-side comparison of Apellis Pharmaceuticals Inc. (APLS) and Kezar Life Sciences Inc. (KZR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLS and KZR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- APLS is the larger of the two at $5.25B, about 97.7x KZR ($53.7M).
- Over the past year, APLS is up 111.8% and KZR is up 64.0% - APLS leads by 47.8 points.
- APLS has been more active in the news (2 items in the past 4 weeks vs 1 for KZR).
- APLS has more recent analyst coverage (25 ratings vs 7 for KZR).
- Company
- Apellis Pharmaceuticals Inc.
- Kezar Life Sciences Inc.
- Price
- $41.05-0.05%
- $7.30-1.02%
- Market cap
- $5.25B
- $53.7M
- 1M return
- +0.48%
- -0.68%
- 1Y return
- +111.85%
- +64.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 2
- 1
- Recent ratings
- 25
- 7
Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Kezar Life Sciences Inc.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Latest APLS
- Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
- SEC Form 15-12G filed by Apellis Pharmaceuticals Inc.
- Director Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- VP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation
Latest KZR
- SEC Form 15-12G filed by Kezar Life Sciences Inc.
- SEC Form EFFECT filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Kezar Life Sciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Kezar Life Sciences Inc.
- Director Berger Franklin M closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- SEC Form 4 filed by Director Garner Elizabeth
- SEC Form 4 filed by Director Cooper Graham K
- Director Kauffman Michael closing all direct ownership in the company (SEC Form 4) (withholding obligation)
- SEC Form 4 filed by Director Wallace Courtney
- CEO Kirk Christopher J. closing all direct ownership in the company (SEC Form 4) (tax liability)